Find your next paid study

GV20 TherapeuticsNCT05669430

Observational

Genetic Testing Uptake Through an Enhanced Oncology Nurse-Led Intervention in Patients With Solid Tumors (GENESIS): A Pilot Study

Genetic factors are a significant determinant of the likelihood of developing various types of cancers. Identification of germline risk can have important impl…

Solid Tumor, Adult

University of California, DavisNCT06436157

SarcomaSolid Tumor, AdultSolid Tumor, Childhood

Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas

This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant…

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03465592

A Biospecimen Collection Study to Facilitate Development of an Ex-Vivo Device Platform for Culture, Immune Assay, and Biobanking of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.

Primary Objective: This is a study to investigate the feasibility of harvesting, expanding, and selecting T lymphocytes from cancer patients and healthy volun…

Solid Tumor, AdultHealthy DonorsCOVID-19 Donors

BioCytics, Inc.NCT00571389

~$10 – $1,050

Solid Tumor, AdultColorectal CancerNon-Small Cell Lung+14 more

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A02 Expression

The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), n…

A2 Biotherapeutics Inc.NCT06682793

Molecular Services and EMR-Laboratory Integration Application (ELIA) for Reducing Leakage and Improving Healthcare Disparities in Cancer Patients

The goal of this observational study is to measure and try to reduce leakage in precision medicine care in the community cancer clinic. The goal of precision m…

Advanced CancerSolid Tumor, AdultMyeloid Malignancy

Bien-Willner Physicians Group PANCT06090513

~$10 – $1,125

Solid Tumor, AdultTriple Negative Breast CancerColorectal Cancer+6 more

A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies

This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Admini…

BioEclipse TherapeuticsNCT04282044

Lung Cancer, Non-small CellLung Cancer MetastaticSolid Tumor, Adult+2 more

KB707-02: A Phase 1/2 Study of Inhaled KB707 in Patients With Advanced Solid Tumor Malignancies Affecting the Lungs

The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumo…

Krystal Biotech, Inc.NCT06228326

Observational

A Randomized Controlled Trial of Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer

The purpose of the randomized control trial is to estimate the effect of an oncology clinical nurse specialist-led early intervention multidisciplinary approac…

Solid Tumor, AdultMetastasis

Good Samaritan Hospital Medical Center, New YorkNCT05947695

Solid Tumor, AdultCarcinoma, Ovarian EpithelialFallopian Tube Neoplasms+3 more

A Phase I/Ib Study of BP1001-A (a Liposomal Grb2 Antisense Oligonucleotide) in Patients With Advanced or Recurrent Solid Tumors

This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety a…

Bio-Path Holdings, Inc.NCT04196257

Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

To determine the recommended phase 2 dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors. Then t…

Solid Tumor, Adult

Virginia Commonwealth UniversityNCT03919292

Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid Tumor+5 more

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conduct…